JP Morgan Chase’s Ionis Pharmaceuticals IONS Stock Holding History

JP Morgan Chase’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.3M	Hold	165,000	–	–	﹤0.01%	2560
2026 Q1	$12M	Buy	+165,000	New	+$13M	﹤0.01%	2515
2025 Q2	–	Sell	-30,000	Closed	-$905K	–	7370
2025 Q1	$905K	Hold	30,000	–	–	﹤0.01%	4420
2024 Q4	$1.05M	Buy	+30,000	New	+$1.12M	﹤0.01%	4602
2024 Q3	–	Sell	-138,700	Closed	-$6.61M	–	7544
2024 Q2	$6.61M	Buy	138,700 +43,800	+46%	+$1.8M	﹤0.01%	2818
2024 Q1	$4.11M	Buy	94,900 +64,900	+216%	+$3.09M	﹤0.01%	3263
2023 Q4	$1.52M	Hold	30,000	–	–	﹤0.01%	4041
2023 Q3	$1.36M	Buy	+30,000	New	+$1.24M	﹤0.01%	3854
2022 Q2	–	Sell	-47,300	Closed	-$1.75M	–	6668
2022 Q1	$1.75M	Hold	47,300	–	–	﹤0.01%	3856
2021 Q4	$1.44M	Hold	47,300	–	–	﹤0.01%	4110
2021 Q3	$1.59M	Buy	+47,300	New	+$1.78M	﹤0.01%	3966
2019 Q3	–	Sell	-50,000	Closed	-$3.23M	–	5843
2019 Q2	$3.23M	Buy	50,000 +14,000	+39%	+$990K	﹤0.01%	3013
2019 Q1	$2.92M	Buy	+36,000	New	+$2.32M	﹤0.01%	3064
2017 Q3	–	Sell	-20,000	Closed	-$1.02M	–	5056
2017 Q2	$1.02M	Buy	+20,000	New	+$931K	﹤0.01%	3418

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JP Morgan Chase's IONS Position: Q2 2026 in Review

JP Morgan Chase increased its Ionis Pharmaceuticals (IONS) stake by 13% in Q2 2026, buying an estimated $23.2M and bringing the position to 2,671,717 shares worth $216M. The position accounts for 0.01% of the portfolio, ranked #727.

JP Morgan Chase first reported a position in IONS in Q2 2013 and has held it in 53 quarters since. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

JP Morgan Chase held 2,671,717 shares of Ionis Pharmaceuticals worth $216M as of Q2 2026.
JP Morgan Chase bought 308,150 Ionis Pharmaceuticals shares in Q2 2026, an estimated $23.2M.
Ionis Pharmaceuticals made up 0.01% of JP Morgan Chase's portfolio in Q2 2026, its #727 holding.
JP Morgan Chase first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.